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Abstract
Objective: The impact of lifetime dietary habits and their role in physical, mental, and social well-being has been the focus 
of considerable recent research. Omega-3 polyunsaturated fatty acids as a dietary constituent have been under the spotlight 
for decades. Omega-3 polyunsaturated fatty acids constitute key regulating factors of neurotransmission, neurogenesis, and 
neuroinflammation and are thereby fundamental for development, functioning, and aging of the CNS. Of note is the fact that 
these processes are altered in various psychiatric disorders, including attention deficit hyperactivity disorder, depression, and 
Alzheimer’s disease.
Design: Relevant literature was identified through a search of MEDLINE via PubMed using the following words, “n-3 PUFAs,” 
“EPA,” and “DHA” in combination with “stress,” “cognition,” “ADHD,” “anxiety,” “depression,” “bipolar disorder,” “schizophrenia,” 
and “Alzheimer.” The principal focus was on the role of omega-3 polyunsaturated fatty acids throughout the lifespan and 
their implication for psychopathologies. Recommendations for future investigation on the potential clinical value of omega-3 
polyunsaturated fatty acids were examined.
Results: The inconsistent and inconclusive results from randomized clinical trials limits the usage of omega-3 polyunsaturated 
fatty acids in clinical practice. However, a body of literature demonstrates an inverse correlation between omega-3 polyunsaturated 
fatty acid levels and quality of life/ psychiatric diseases. Specifically, older healthy adults showing low habitual intake of omega-3 
polyunsaturated fatty acids benefit most from consuming them, showing improved age-related cognitive decline.
Conclusions: Although further studies are required, there is an exciting and growing body of research suggesting that omega-3 
polyunsaturated fatty acids may have a potential clinical value in the prevention and treatment of psychopathologies.
Keywords: omega-3 polyunsaturated fatty acids (n-3 PUFAs), depression, schizophrenia, bipolar disorder, Alzheimer’s 
disease
Introduction
Despite the improved pharmacological approaches that mod-
erately buffer the worldwide burden of poor mental health, a 
recent finding suggests that mental illnesses will continue to 
rise worldwide during the coming decades (Baxter et al., 2013). 
The general transition to more calorically dense, processed diets 
and reduced physical activity have had a significant impact on 
the overall health of individuals in developed nations and are 
associated with an increased incidence of psychopathologies 
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such as anxiety and depression (Logan and Jacka, 2014). 
Accumulating translational evidence implicates the quality of 
diet as a crucial and common determinant for mental disorders 
(McNamara et al., 2015). Within the brain, omega-3 polyunsat-
urated fatty acids (n-3 PUFAs) have been under the spotlight 
for decades. However, only recently has research looked into 
the critical role of n-3 PUFAs in brain function and structure 
throughout the lifespan. n-3 PUFAs constitute key regulating fac-
tors of neurotransmission, neurogenesis, cell survival, and neu-
roinflammation and are thereby fundamental for development, 
functioning, and aging of the CNS (Mischoulon and Freeman, 
2013). Importantly, these processes are altered in various psy-
chiatric disorders, including attention deficit hyperactivity dis-
order (ADHD), schizophrenia, major depression, and Alzheimer’s 
disease (Sinn et al., 2010). Despite this evidence, the concept of 
n-3 PUFAs as a clear therapeutic compound for mental disorders 
still needs to be clarified. The purpose of this review is to further 
explore the role of n-3 PUFAs, which have been gaining increas-
ing credence as potential targets for the development of novel 
strategies for the maintenance of mental health in the preven-
tion and amelioration of psychopathology (Figure 1).
n-3 PUFAs in Early-Life: From 
Embryogenesis to Adolescence
Brain development is a sequential anatomical process charac-
terized by specific well-defined stages of growth and matura-
tion. It has become more evident that this process is influenced 
by n-3 PUFAs. Specifically, the levels of docosahexaenoic acid 
(DHA), the most abundant component of the n-3 PUFAs fam-
ily, increase sharply along the perinatal period. In rats, the first 
important step of acquisition of DHA takes place in the embry-
onic phase and in the first 3 postnatal weeks of life, whereas in 
humans this period goes between the last trimester of gestation 
and the first 6 to 10 months after birth (Clandinin et al., 1980a, 
1980a). At these stages of life, the foetal metabolic capability to 
convert the precursor of the n-3 PUFAs family, α-linolenic acid 
(ALA), to DHA is extremely limited (<0.2% in children). Indeed, 
it is the mother that guarantees an adequate delivery of DHA to 
the fetus through the placenta. (Innis, 2007).
The Perinatal Lipid Nutrition Project and The Early Nutrition 
Programming Project have recently developed consensus 
recommendations concerning dietary fat intake for pregnant 
and lactating women. They recommend a minimum DHA intake 
of 200 mg/d (Koletzko et  al., 2007). Interestingly, supplementa-
tion of n-3 PUFAs during pregnancy not only increases breast 
milk DHA content but also results in slightly longer gesta-
tion as well as reduced risk of preterm delivery (Singh, 2005). 
Accordingly, infants born prematurely show less accumulation 
of DHA in the brain (Barcelo-Coblijn and Murphy, 2009). However, 
the increased supply of DHA to the developing fetal nervous sys-
tem leads to a progressive depletion of maternal plasma DHA 
(Smuts et al., 2003). Of relevance, in a cross-national ecological 
analysis, reduced levels of maternal milk DHA and lower sea-
food consumption correlated with higher rates of postpartum 
depression (Hibbeln, 2002). Therefore, diets enriched in n-3 
PUFAs are recommended to both restore the depletion of DHA 
in the mother as well as to look after the needs of the fetus and 
suckling infant.
Animal studies reveal n-3 PUFAs as guarantors of proper 
brain development in early postnatal life (Lei et al., 2013). n-3 
PUFA supplementation has been shown to protect from neu-
ronal loss and decreased neurogenesis in the cerebral cortex 
and hippocampus of neonates (Lei et  al., 2013). Furthermore, 
this effect can be long-lasting and show further benefits in 
neurocognitive function later in adulthood (Lei et al., 2013). In 
humans, Jensen et al. (2005) have shown a higher Psychomotor 
Development Index in breastfed infants of mothers who under-
went DHA administration (200 mg/d) for a period of 4 months. 
Psychomotor development, eye-hand coordination, and visual 
acuity were all improved after DHA algal-oil treatment. However, 
these improvements were limited to infants 30 months old and 
no further advantages on mental development were found. 
Although of relevance, this study has limitations in terms of 
treatment duration and assessment instruments. A  differ-
ent study measured IQ in children whose mothers underwent 
maternal supplementation with cod liver oil (1183 mg/10 mL 
DHA, 803 mg/10 mL eicosapentaenoic acid [EPA]) started from 
week 18 until 3 months after delivery (Helland et al., 2003). The 
scoring of the Mental Processing Composite of the Kaufman 
Assessment Battery for Children was increased by 4 points in 
4-year-old children who were born to mothers who had taken 
cod liver oil enriched in DHA and EPA. However, only 84 children 
of the 590 pregnant women enrolled in the study completed 
Figure 1. Omega-3 polyunsaturated fatty acids [(n-3) PUFAs] throughout the lifespan. n-3 PUFAs represent essential components of the cellular membrane and consti-
tute key regulating factors of neurotransmission, neurogenesis, stress response, inflammation, and emotional states. Thereby, they are fundamental for development, 
functioning, and aging of the CNS throughout the lifespan. n-3 PUFAs, mainly acting on the factors mentioned above, contribute to the maintenance of mental health, 
in the prevention and amelioration of psychopathology.
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the Kaufman Assessment Battery for Children at 4  years of 
age. Another similar study has shown higher mental process-
ing scores and high degree of stereopsis and stereo acuity in 
children 3.5 years old whose mothers received a DHA-rich diet 
(Williams et al., 2001). Given the importance to maintain proper 
DHA levels during the neonatal period of life, the content and 
kind of fatty acids introduced in the body are of importance. In 
fact, infants fed formula with 0.4% or 2.4 % energy from ALA 
had 2.3 ± 0.2 and 2.2 ± 0.3 g/100 g fatty acids as DHA in plasma, 
respectively, despite the large difference in ALA intake, whereas 
infants fed formula with only 0.12 % energy from DHA had 
plasma DHA levels of 5.2 ± 0.2 g/100 g (Innis, 2007).
n-3 PUFAs maintain their importance in brain development 
and functioning during adolescence (Table 1). At this stage of life, 
rats fed with an n-3 PUFA-deficient diet tend to have decreased 
n-3 PUFA mass (82% less) compared with control (Bondi et al., 
2014). Such animals show less exploratory behavior, weaker 
memory performance, and increased tyrosine hydroxylase 
expression (dopamine [DA] precursor) in the dorsal striatum.
In humans, Kuratko et  al. (2013) provided a systematic 
review based on 15 publications regarding the influence of 
DHA in learning and behavior in healthy children. The studies 
differed in purpose and design, and some did not achieve a 
consistent conclusion regarding DHA’s effect on specific cogni-
tive tests. However, the analysis found benefits of DHA supple-
mentation in brain activity and school performance from over 
one-half of the considered studies. A landmark study showing 
improved brain activity after DHA supplementation dates back 
to 2010 (McNamara et al., 2010a). McNamara et al. showed for 
the first time regulation of cortical metabolic function and cog-
nitive development exerted by DHA concentrations in the grey 
matter of healthy boys during sustained attention (McNamara 
et al., 2010a). The study was conducted in 33 subjects (9 years 
old) who were assigned to receive placebo or 1 of the 2 doses 
of DHA (400 mg/d; 1200 mg/d) for 8 weeks. A longitudinal study 
in arctic Quebec has revealed a relation within school-age 
children with higher DHA cord plasma concentration and 
memory function (Boucher et al., 2011). Despite this interest-
ing finding, a previous study conducted in DHA-fed healthy 
children in the UK did not show any improvement on cogni-
tive performance and learning (Kennedy et al., 2009). However, 
other studies have observed benefits of n-3 PUFAs, particu-
larly in malnourished subjects. For instance, improvements in 
learning and cognitive performance have been shown in n-3 
PUFA-supplemented, malnourished children 7 to 9 years old in 
South Africa (Dalton et al., 2009) and 8- to 12-year-old Mexican 
children (Portillo-Reyes et al., 2014), although, no benefits were 
found in 6- to 10-year-old malnourished children from India 
(Muthayya et al., 2009) and Indonesia (Osendarp et al., 2007). 
The discordance between these studies may be accounted for 
by differences in the extent of malnutrition. Moreover, further 
discrepancies can be due to differences in the experimental 
plan such as supplements used, different dosages, and dura-
tion of the trials. Overall, the current research supports the 
view that adequate intake of DHA since prenatal life may 
have a positive impact on brain activity, learning, and cog-
nition in healthy children. Indeed, being components of cell 
membranes, n-3 PUFAs are involved in important phases of 
brain development such as neurogenesis, myelination, syn-
aptogenesis, and dendritic arborisation, which are in continu-
ous flux during development and learning (Wurtman, 2014). 
Thus, this raises the possibility that n-3 PUFAs may have a 
beneficial effect on neurodevelopmental psychiatric disorders 
(McNamara and Carlson, 2006).
n-3 PUFAs: Implication for Childhood 
Disorders
Deficits in n-3 PUFAs have been associated with higher risk of 
development of childhood disorders such as ADHD (Richardson 
and Ross, 2000). In a cross-sectional study, Burgess et al. (2000) 
observed that 40% of recruited ADHD subjects (53 ADHD 6- to 
12-year-old boys) had significantly lower proportions of plasma 
DHA and EPA and greater frequency of n-3 PUFAsdeficiency 
syndrome such as thirst, frequent urination, and dry hair. 
Importantly, such physical signs linked with deficit in n-3 PUFAs 
are consistent in ADHD (Richardson et  al., 2000). Moreover, 
behavioral and learning problems, such as anomalous visual, 
motor, attention, and language processing, have been linked to 
lower n-3 PUFAs plasma levels (Richardson, 2004). The reason 
for lower n-3 PUFAs levels in ADHD is unknown. Evidence sug-
gests that testosterone can impair the biosynthesis of n-3 PUFAs 
while estrogens are positively related with the conversion of 
DHA from ALA both in rodents (Marra and de Alaniz, 1989) and 
humans (Childs et al., 2008). This may explain the higher preva-
lence of ADHD in males than in females.
In animal studies the spontaneously hypertensive rat is 
generally used as a model of ADHD (Meneses et  al., 2011). 
Spontaneously hypertensive rat fed n-3 PUFA (EPA-DHA)-
enriched diet (n-6:n-3 PUFAs ratio of 1:2.7), from gestational 
phase until postnatal day 50, partially ameliorated ADHD-like 
behavior by improving reinforcer-controlled activity, impulsive-
ness, and inattention (Dervola et al., 2012). Moreover, such a diet 
increased the DA and serotonin turnover ratio together with 
decreased levels of glutamate in the striatum of the same ani-
mals (Dervola et al., 2012). These neurotransmitters are thought 
to be altered in ADHD animal models (Gainetdinov et al., 2001) 
and ADHD young subjects (Paloyelis et al., 2012).
In humans, supplementation with PUFAs (480 mg DHA, 80 mg 
EPA, 40 mg arachidonic acid [AA], 96 mg γ-linolenic acids, and 
24 mg α-tocopheryl acetate) improved ADHD children’s oppo-
sitional defiant behavior from a clinical to a nonclinical range 
(Stevens et al., 2003). In this study, both parents and teachers 
rated improvement in conduct problems and attention difficul-
ties after 4 months of treatment. However, more than one-half 
of the patients were prescribed medication for ADHD, making it 
difficult to attribute the observed improved symptoms to the n-3 
PUFA treatment. A similar PUFA mixture (480 mg DHA, 186 mg 
EPA, 96 mg γ-linolenic acids, 42 mg AA, and 60 IU vitamin E per 
day), supplemented for 12 weeks, showed improvement in anxi-
ety/shy tests, cognition, inattentiveness, hyperactivity/impul-
siveness, total DSM-IV index, and Conners total global index in 
children with learning difficulties (Richardson and Puri, 2002). 
However, none of the subjects were formally diagnosed with 
ADHD and the sample size was small (41 children, 8–12 years 
old). Although the studies reported above seem to be encourag-
ing, 3 recent systematic reviews have reported only minor n-3 
PUFA effect in reducing ADHD symptoms. Grassman et al. (2013) 
reported mild behavioral and cognitive improvement in ADHD 
children after treatment with low doses of n-3 PUFAs. However, 
the studies included in their analysis were heterogeneous, had 
small sample sizes, and only a limited number were placebo 
controlled. Bloch and Qawasmi (2011) have reported a modest 
effect in the treatment of ADHD after treatment with high doses 
of n-3 PUFAs (especially EPA) in comparison with current phar-
macotherapies such as psychostimulants, atomoxetine, or α(2) 
agonists. Gillies et al. (2012) reported improvement after com-
bined n-3 PUFA and n-6 PUFA supplementation only in a minor-
ity of the studies that met the inclusion criteria of their review. 
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Table 1. n-3 PUFA Impact in Healthy Adolescents
Participants Treatment
Length  
of Trial Measurements Outcomes References
6–11 years,  
low-income  
iron-deficient 
children, (n = 321,  
z n = 288).
(1) Iron + fish oil; (2) Iron 
+ placebo; (3) Fish oil + 
placebo; (4) Placebo + 
placebo. Fish oil = 0.5 g/d 
LC omega-3 (0.42 g DHA + 
0.08 g EPA).
8.5 months. HVLT LC omega-3 PUFA without 
iron had negative effects on 
working memory in children 
with iron deficiency anemia 
and long-term memory 
and retrieval in girls with 
iron deficiency, whereas 
boys with iron deficiency 
performed better.
(Baumgartner 
et al., 2012)
7–9 years, low-income, 
marginally nourished 
indigenous children 
(n = 183, analysis on 
n = 155).
Fish flour bread spread 
provided at school 
(~0.89 g/week DHA 
[0.13 g/d]) vs control 
bread spread.
6 months. HVLT, spelling test, 
reading test
↑ Verbal learning ability, 
memory, and spelling.  
Effects more pronounced  
in children with lower 
baseline performance scores.
(Dalton et al., 
2009)
10–12 years (n = 90, 
analysis on n = 86).
(1) Low-dose algal oil: 
0.4 g DHA; (2) High-dose 
algal oil: 1.0 g/d DHA; (3) 
Placebo (vegetable oil).
8 weeks. Cognitive  
performance
Word recognition task: low 
dose: faster performance; 
high dose: slower 
performance.
(Kennedy et al., 
2009)
8–10 years (n = 450, 
analysis on n = 348).
Fish oil (0.4 g DHA + 0.06 g 
EPA)/d + micronutrients 
vs placebo (olive oil).
16 weeks. KBIT-2, WIAT-2,  
WMTB-C, creature 
counting, MFFT,  
comPET, SNAP-IV, SDQ.
No treatment effects. (Kirby et al., 
2010)
8–10 year boys (n = 38, 
analysis on n = 33).
(1) Low-dose algal oil: 
0.4 g/d DHA; (2) High- 
dose algal oil: 1.2 g/d 
DHA; (3) Placebo (corn 
oil).
8 weeks. Sustained  
attention test,  
fMRI
Both dosages ↑ activation of 
the dorsolateral prefrontal 
cortex during sustained 
attention task. No effect  
on attention or reaction  
time of attention.
(McNamara 
et al., 2010a)
6–10 years,  
low-income, 
marginally  
nourished (n = 598, 
analysis on n = 550).
(1) High micronutrients + 
0.93 g ALA + 0.10 g DHA/d; 
(2) High micronutrients 
+ 0.14 g/d ALA; (3) Low 
micronutrients + 0.93 g  
ALA + 0.10 g DHA/d (4)  
Low micronutrients + 
0.14 g/d ALA.
12 months. Cognitive test  
battery
No treatment effects. (Muthayya 
et al., 2009)
6–10 years Australia: 
well nourished, 
(n = 396, analyzed 
n = 276) Indonesia: 
marginally 
nourished (n = 384, 
analyzed n = 367).
(1) High micronutrients; 
(2) DHA + EPA (0.09 g 
DHA + 0.02 g EPA)/d; (3) 
Micronutrients + DHA 
+ EPA (as above); (4) 
Placebo.
12 months. Cognitive test  
battery
No treatment effects. (Osendarp et al., 
2007)
3–13 years, indigenous 
children with low 
literacy ability 
(n = 408).
Fish oil 0.75 g LC omega-3 
per school day (0.56 g 
EPA + 0.17 g DHA) plus 
0.06 g/d gamma  
linolenic acid vs  
placebo (palm oil).
20 weeks. WRAT4, DAP,  
MAP, CBRS
Nonverbal cognitive 
development (Draw-A 
Person): Improvements  
with strongest effects  
in 7- to 12-year olds.
(Parletta  
et al., 2013)
8–12 years, mild- 
moderately 
malnourished  
(n = 59, analysis  
on n = 50).
Fish oil 0.45 g/d LC 
omega-3 (0.18 g EPA + 
0.27 g DHA) vs placebo 
(soybean oil).
3 months. Anthropometric measures, 
neuropsychological 
battery test
↑ Processing speed, visual- 
perceptive capacity, 
attention, executive  
function.
(Portillo-Reyes 
et al., 2014)
7–9 years, 
underperforming in 
reading (≤33rd  
centile) (n = 362).
Algal oil: 0.6 g/d DHA vs 
placebo (corn/ 
soybean oil).
16 weeks. Age-standardized 
measures of reading, 
working memory, and 
parent- and teacher- 
rated behavior.
Treatment ↑ reading. (Richardson 
et al., 2012)
Abbreviations: CBRS, Comprehensive Behaviour Rating Scales; DAP, The Draw-A-Person; HVLT, Hopkins Verbal Learning Test; KBIT-2, Kaufman Brief Intelligence Test, 
Second Edition; MAP, Matrix Analogies Test; MFFT, Matching Familiar Figures Task; SDQ, Strengths and Difficulties Questionnaire; SNAP-IV, Swanson, Nolan, and 
Pelham rating scale for ADHD; WIAT-2, Wechsler Individual Achievement Test, Second Edition; WMTB-C, Working Memory Test Battery for Children; WRAT-4, Wide 
Range Achievement Test: Fourth Edition.
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Given its evidence of modest efficacy, it may be reasonable to 
investigate n-3 PUFAs as a supplement to traditional pharmaco-
logic interventions. Future studies need to be adequately pow-
ered and placebo controlled and use adequate dosage, (Table 2).
n-3 PUFAs in Adulthood: Stress Response
In adulthood, full brain development is already achieved. 
However, at this stage of life stressful life events can alter mood 
states and cognition, increasing susceptibility to psychopathol-
ogies (Cattaneo et  al., 2015). n-3 PUFAs seem to play a role in 
the regulation of the stress-response influencing the activity 
of the hypothalamic–pituitary–adrenal (HPA) axis. In humans 
(7 volunteers), the stimulation by 30 minutes of mental stress 
(mental arithmetic’s and Stroop’s test) of plasma epinephrine, 
cortisol, and energy expenditure were all significantly blunted 
by 3 weeks of 7.2 g/d fish oil administration (Delarue et al., 2003). 
However, the subjects were tested before and after 3 weeks 
of n-3 PUFA supplementation; thus, a possible effect of accli-
matization due to the repetition of the testing procedure over 
time should be taken into account. Similarly, ACTH and cortisol 
plasma levels were blunted by 4 weeks of 7 g/d fish oil supple-
mentation prior lipopolysaccharide (2 ng/kg)-induced neuroen-
docrine response (Michaeli et al., 2007). In contrast with the n-3 
PUFA antiinflammatory effect (Grimm et al., 2002), high levels of 
cytokines were not reversed by n-3 PUFAs, perhaps due to a too 
low content of EPA (17%) and DHA (11%) in the fish oil supple-
ment. Indeed, 2.5 g/d of n-3 PUFAs (2 g EPA, 0.35 g DHA) supple-
mentation showed reduction of stimulated interleukin 6 (IL-6) 
and tumour necrosis factor plasma levels in healthy medical 
students. Interestingly, this was associated with reduced anxi-
ety symptoms in healthy students without an anxiety disorder 
diagnosis (Kiecolt-Glaser et  al., 2011). This evidence acquires 
more interest, since stress can exert a pivotal role in memory 
and cognition (McEwen, 2007). Researchers at the University of 
Pittsburgh have determined that n-3 PUFAs can enhance cog-
nition in young individuals. Healthy young adults (18–25 years 
of age) after 6  months of n-3 PUFA supplement, mostly DHA 
(750 mg/d) and EPA (930 mg/d), experienced improvement in 
working memory (Narendran et  al., 2012). Working memory 
assessment was performed using a verbal n-back task that used 
3 loads of working memory (1-, 2-, and 3-back) (Abi-Dargham 
et  al., 2002). In addition to that, prior to supplementation of 
n-3 PUFAs, higher red blood cell DHA levels were significantly 
correlated with working memory in a group of young adults. 
Interestingly, a similar association between high DHA plasma 
levels and improved cognitive function was previously observed 
in a sample of 208 healthy subjects (30–54 years of age; Muldoon 
et al., 2010). DHA, but not other n-3 PUFAs, was associated with 
better scores on tests of nonverbal reasoning, mental flexibility, 
working memory, and vocabulary. Another study conducted in 
Australia showed 6 weeks of 6 g/d fish oil intake (1.5 g DHA, 360 g 
EPA) were enough to ameliorate the Perceiving Stress Scale scor-
ing in stressed university staff (Bradbury et al., 2004). Due to a 
lack of investigation, further research is warranted to elucidate 
the mechanisms by which n-3 PUFAs enhance cognitive perfor-
mance in healthy individuals (Table 3).
n-3 PUFAs and Psychopathologies
Major Depressive Disorder
Since the 19th century, the incidence of major depressive dis-
order (MDD) in Western countries seems to have increased. 
In contrast, the dietary intake of n-3 PUFAs has dramatically 
declined in favor of n-6 PUFA intake (Molendi-Coste et al., 2011). 
Joseph Hibbeln was one of the first investigators to draw atten-
tion to the importance of n-3 PUFAs in psychiatric disorders. In 
1998, Hibbeln showed a cross-national significant negative cor-
relation between worldwide fish consumption and prevalence 
of MDD (Hibbeln, 1998). Moreover, higher n-6/n-3 ratios, such 
as the AA/EPA ratio, has been detected in blood samples (Lin 
et  al., 2010) and red blood cell phospholipids (Logan, 2003) of 
depressed patients. Accordingly, n-3 PUFA concentrations in the 
blood reflect an accurate, although not identical, representation 
of n-3 PUFAs levels in the brain (Horrobin, 2001). Lower DHA lev-
els have been found in the postmortem orbitofrontal cortex of 
MDD patients (McNamara et al., 2007). Moreover, lower n-3PUFA 
levels have been found in chronic hepatitis C viral infection 
patients that developed interferon (IFN)-induced depression 
after IFN-α intervention. This finding identifies both n-3 PUFA-
related genotypes and n-3 PUFA levels as risk factors for IFN-
induced depression (Su et al., 2010). However, these findings do 
not show that fish consumption can cause differences in the 
prevalence of MDD or that eating fish or fish oils is useful in 
treatment. One double-blind, placebo-controlled study investi-
gated the effect of EPA as adjunct to antidepressant therapy in a 
group of 20 MDD diagnosed patients. Although this was a small 
study (17 women, 3 men), the addition of 2 g of EPA to standard 
antidepressant medication showed highly significant benefits 
by week 3 of treatment. Primarily, EPA showed effects on insom-
nia, depressed mood, and feelings of guilt and worthlessness 
(Nemets et al., 2002). In 2002, Peet and Horrobin observed that a 
specific EPA dosage (1 g/d) was effective in ameliorating depres-
sive symptoms in subjects with persistent depression despite 
ongoing treatment with antidepressant. In this 12-week, rand-
omized, double-blind, placebo-controlled trial, 53% of the sub-
jects who received EPA (17 subjects) achieved a 50% reduction 
on the Hamilton Depression Rating Scale score. In addition, the 
EPA had a broad-spectrum positive effect leading to improve-
ments in anxiety, sleep, lassitude, libido, and suicidal ideation 
(Peet and Horrobin, 2002). Moreover, a 2-week, double-blind, 
placebo-controlled trial conducted in a group of 162 patients 
showed n-3 PUFA efficacy in the prevention of IFN-induced 
depression in hepatitis C virus patients (Su et  al., 2014). Both 
DHA (1.75 g/d) and EPA (3.5 g/d) significantly delayed the onset 
of IFN-induced depression after 24 weeks of IFN-α treatment. 
Despite that, only EPA-treated patients showed lower incident 
rates of IFN-induced depression (10% vs 30% for placebo [oleic 
oil, 4 g/d], P = .037). Although clinical outcomes on the effect of 
EPA on major depression seem to be promising, trials using 
DHA are inconclusive. Thirty-six subjects with major depression 
assigned to receive DHA (2 g/d) for 6 weeks did not show differ-
ences in the score of the Montgomery-Asberg Depression Rating 
Scale compared with the placebo-treated group (Marangell 
et al., 2003). A recent meta-analysis focused on the hypothesis 
that EPA represents the key compound of the n-3 PUFA family 
having effects in the treatment of major depression. Fifteen tri-
als (916 total participants) using n-3 PUFAs as either a mono or 
adjunctive therapy were analyzed. Studies were selected based 
on prospective, randomized, double-blinded, placebo-controlled 
study design, if depressive episode was the primary complaint 
with or without comorbid medical conditions and, if appropri-
ate outcome measures were used to assess depressed mood. 
This meta-analysis concluded that n-3 PUFA supplements with 
>60% of EPA (in a dose range of 200 to 2200 mg/d in excess of 
DHA) ameliorated the clinical condition. However, doses con-
taining primarily DHA or <60% EPA were not effective against 
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Table 2. n-3 PUFA Impact on Mental Illnesses in Early Life and Adolescence
Participants Treatment Length of Trial Measurements Outcomes References
6–12 year old (78% boys); 
idiopathic ADHD 
diagnosis; were being 
treated successfully with 
medication (n = 54).
345 mg DHA (algae- 
derived) or undefined 
placebo.
16 weeks. CPRS; CBC; TOVA; 
CCT.
Treatment = placebo on all 
measures.
(Voigt et al.,  
2001)
6–13 year old (78% boys); 
ADHD diagnosis; 
high FADS; some on 
medication (equally 
allocated to conditions) 
(n = 50).
96 mg GLA, 40 mg AA, 
80 mg EPA, 480 mg 
DHA, 24 mg Vit E or 
olive oil placebo.
16 weeks. DBD; ASQ; CPT; 
WJPEB-R; FADS.
Treatment > placebo: DBD- 
Conduct (parents); DBD- 
Attention (teachers). Other 
14 outcome measures 
nonsignificant.
(Stevens et al.,  
2003)
6–12 year old (80% boys); 
ADHD diagnosis; 15% 
medicated; 82% comorbid 
conditions (n = 40).
100 mg EPA, 514 mg DHA, 
or olive oil placebo 
(supplied in soymilk 
and bread).
8 weeks. DTVP; STM; CPT; 
Other.
Treatment = placebo on all 
measures (except that 
placebo > treatment on CPT 
and STM).
(Hirayama  
et al., 2004)
8–12 year old (62% 
boys); normal IQ; low 
reading ability; above 
average ADHD scores 
on Conners’ Index; no 
participants in treatment 
for ADHD (n = 29).
864 mg LA, 42 mg AA, 
96 mg ALA, 186 mg 
EPA, 480 mg DHA, 60 
iµ Vit E or olive oil 
placebo.
12 weeks. CPRS. Treatment > placebo: CPRS; 
Cognitive problems/ 
inattention; Anxious/shy; 
Conners’ global index; 
DSM inattention; DSM 
hyperactive/impulsive; 
Conners’ ADHD Index.
(Richardson  
and Puri,  
2002)
5–12 year old (77% 
boys); Developmental 
Coordination Disorder, 
one-third with ADHD 
symptoms in clinical 
range, not in treatment; 
IQ > 70 (n = 117).
60 mg AA, 10 mg GLA, 
558 mg EPA, 174 mg 
DHA, 9.6 mg Vit E or 
olive oil placebo.
12 weeks active vs 
placebo; 1-way 
crossover to 
active treatment 
for 12 weeks.
MABC; WORD; 
CTRS.
Treatment > placebo: WORD; 
CTRS Oppositional behavior; 
cognitive problems/
inattention; hyperactivity; 
anxious/shy; perfectionism; 
social problems; Conners’ 
index; DSM-IV inattention, 
hyperactive/impulsive.
(Richardson  
and  
Montgomery, 
2005)
7–12 year old (74% boys); 
ADHD symptoms 
in clinical range; 
unmedicated (n= 132, 
questionnaire data 
available for 104).
60 mg AA, 10 mg GLA, 
558 mg EPA, 174 mg 
DHA, 9.6 mg Vit E, or 
palm oil placebo.
15 weeks active vs 
placebo; 1-way 
crossover to 
active treatment 
for 15 weeks.
CPRS, CTRS 
Vocabulary, 
subtests from 
WISC-III & TEA- 
ch, Stroop.
Treatment > placebo 
CPRS: cognitive 
problems/inattention; 
hyperactivity; ADHD 
Index; restless/impulsive; 
DSM-IV hyperactive/
impulsive; oppositional. 
Treatment = placebo on 
other subscales and CTRS.
Treatment > placebo 
on creature counting 
and vocabulary. 
Treatment = placebo on 
other cognitive tests.
(Sinn and  
Bryan, 2007;  
Sinn et al.,  
2008)
8–18 year old with 
diagnosed ADHD, 
unmedicated (85% 
males) (n = 75).
60 mg AA, 10 mg GLA, 
558 mg EPA, 174 mg 
DHA, 9.6 mg Vit E or 
olive oil placebo.
3 months active vs 
placebo; 1-way 
crossover to 
active treatment 
for 3 months.
Investigator-rated 
ADHD Rating 
Scale-IV; CGI.
Treatment = placebo overall 
Treatment > placebo in 
subgroups with inattentive 
subtype and comorbid 
neurodevelopmental 
disorders.
(Johnson  
et al., 2009)
7–12 year old (79% male) 
with ADHD/ 
ADHD symptoms (50% 
diagnosed) (n = 54, 45 
with bloods).
1 g EPA-rich oil, 1 g DHA 
rich oil or sunflower 
oil placebo.
3 x 3 crossover 
(4 months on 
each treatment).
CPRS, reading, 
writing, 
vocabulary,  
TEA-ch.
Treatment = placebo in 
12-month crossover.
Over 4 months erythrocyte 
DHA increases associated 
with improvements on 
CPRS - oppositional behavior, 
anxiety/ 
shyness – divided attention 
and reading. In subgroup 
with learning difficulties 
(n = 16 with blood) also on 
CPRS hyperactivity/ 
impulsivity and spelling.
(Milte et al., 
2011)
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primary depression. Moreover, trial duration (4–16 weeks) was 
not a predictor of outcomes, suggesting that EPA improvements 
may not be limited to the initial treatment period (Sublette et al., 
2011). Albeit, it is not possible to recommend n-3 PUFAs as either 
a mono or adjunctive therapy in major depression as yet, though 
the current research is strong enough to justify further studies.
Bipolar Disorder and Schizophrenia
To date, the link between n-3 PUFA levels and bipolar disor-
der/schizophrenia is poorly understood. n-3 PUFAs can have a 
slight beneficial effect on depressive symptoms when added to 
an existing psychopharmacological maintenance treatment for 
bipolar disorder. For instance, 30 patients with bipolar disorder 
were randomized to receive 9.6 g/d of n-3 PUFAs (EPA 6.2 g, DHA 
3.2 g) or placebo (olive oil) in addition to their ongoing usual 
treatment. The n-3 PUFAs patient group showed a significantly 
longer period of remission than the placebo group as assessed 
by the Kaplan-Meier survival analysis (Stoll et  al., 1999). In a 
second study, patients with bipolar disorder were randomized 
to receive either 1to 2 g/d ethyl-EPA (n = 24–25, respectively) or 
placebo (paraffin oil, n = 26) in addition to their ongoing usual 
treatment (Frangou et  al., 2006). The EPA treatment, without 
apparent benefit of 2 g over 1 g EPA, significantly improved the 
Hamilton Rating Scale for Depression together with the Clinical 
Global Impression Scale. Nevertheless, current data on the effi-
cacy of DHA and EPA in the treatment of bipolar disorder are 
insufficient for us to draw definite conclusions that can guide 
clinical practice.
Despite the large paucity of data, it seems that n-3 PUFAs may 
be of help in reducing psychotic-like symptoms (Schlogelhofer 
et  al., 2014). Eighty-one participants with subthreshold psy-
chosis were followed for 12  months to investigate the rate of 
progression to first-episode psychotic disorder. Previously, 
one-half of the group underwent a 12-week intervention period 
of 1.2 g/d n-3 PUFAs or placebo. Only 5% of the n-3 PUFA group 
had transitioned to psychotic disorder in contrast to a 27.5 % in 
the control group. Moreover, n-3 PUFA intake ameliorated posi-
tive, negative, and general symptoms assessed by the Positive 
and Negative Syndrome Scale (Amminger et al., 2010). Overall, 
well-designed and executed randomized controlled trials in this 
field are clearly lacking, and the need for such high-quality pri-
mary research is acute. Study duration should be long enough to 
ensure that the n-3 PUFAs can be fully absorbed into brain cell 
membranes and therefore should ideally be 3 months at a mini-
mum. Finally, the dose and composition of the n-3 PUFA supple-
ment should be modelled on current evidence, which suggests 
that 1 to 2 g/d of EPA or majority EPA supplement may be the 
most effective form of the treatment, although further research 
into the efficacy of varied compositions and doses of n-3 PUFA 
treatment is also necessary (Table 4).
n-3 PUFAs in Elderly
Clinical studies have been carried out to elucidate the role of 
n-3 PUFAs in healthy older subjects (Table 5). One of the largest 
randomized, controlled trials to date recruited 867 cognitively 
healthy subjects (70–79 years old) and did not reveal improved 
cognitive functioning in the California Verbal Learning Test 
after 24  months of treatment (200 mg EPA plus 500 mg DHA) 
(Dangour et  al., 2010), even though at the end of the study, 
the n-3 PUFA serum levels were higher compared with the 
placebo group (olive oil) and the n-3:n-6 PUFA ratio was rela-
tively high in both groups. Moreover, all the recruited subjects 
showed a high cognitive functioning at the beginning of the 
study, as assessed by the Mini-Mental State Examination. This, 
the authors suggest, is the reason for the negative findings. 
In another study, higher administration of n-3 PUFAs (900 mg 
Participants Treatment Length of Trial Measurements Outcomes References
5–17 years with Autistic 
Disorder (81.9% male) 
(n = 13).
1.5 g/d n-3 PUFA  
(0.84 g EPA, 0.7 g  
DHA), Vit E or  
coconut oil placebo.
6 weeks parallel 
design.
Aberrant Behavior 
Checklist.
Treatment > placebo for 
stereotypy and  
hyperactivity (trends  
with large effect sizes).
Treatment = placebo on  
3 other subscales.
(Amminger 
et al., 2007)
6–12 year old; 25% girls 
children with MDD 
(n = 20).
2 g ethyl-EPA (96% from 
fish oil) or placebo, 
Vit E.
4 weeks parallel 
design, adjunctive 
therapy.
HDRS. Treatment > placebo at  
weeks 2, 3, and 4 on HDRS 
score and on core  
depressive symptom 
subscales.
(Nemets et al., 
2006)
Mean-age = 16.4 with 
ultra-high risk (UHR) 
for psychosis, (n = 81 
individuals, 27 males,  
54 females).
~1.2 g ω-3 PUFAs (0.7 g 
EPA, 0.48 g DHA,  
7.6 mg vitamin E).
12 weeks. Gaussian Process 
Classification.
Treatment > placebo on GPC (Sinn et al., 2010)
8–14 year old, (n = 80 boys, 
41 ADHD, 39 controls).
10 g of margarine daily, 
enriched with either 
650 mg of EPA/ 
DHA or placebo.
16 weeks. CBCL, SWAN, TRF, 
fMRI.
Treatment > parent- 
rated attention in both 
ADHD control.
(Bos et al., 2015)
Abbreviations: ASQ, Conners’ Abbreviated Symptom Questionnaires; CBC, Child Behaviour Checklist; CCT, Children’s Colour Trails test; CGI-S, Clinical Global Impres-
sion-Severity; CPRS, Conners’ Parent Rating Scales; CPT, Conners’ Continuous Performance Test; CTRS, Conners’ Teacher Rating Scales; DBD, Disruptive Behaviour 
Disorders rating scale; FADS, fatty acid deficiency symptoms; GLA, γ-linolenic acids; HDRS, Hamilton Depression Rating Scale; MABC, Movement Assessment Battery 
for Children; MDD, major depressive disorder; Stroop, Stroop color-word test; STM, Short-term memory; TEA-ch, Test of Everyday Attention for children; TOVA, Test 
of Variables of Attention; WISC-III, Wechsler Intelligence Scale for Children, version 3; WORD, Wechsler Objective Reading Dimensions; WJPEB-R, Woodstock-Johnston 
Psycho-Educational Battery – Revised.
Table 2. Continued
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DHA) for 24 weeks showed improvements in verbal recognition 
memory and visuospatial learning in elderly subjects with low 
habitual intake of DHA (Yurko-Mauro et al., 2010). Accordingly, 
higher concentration (1.3 g DHA and 0.45 g EPA) and longer 
duration (12 months) of n-3 PUFAs showed improvement in dif-
ferent cognitive domains of a neuropsychological battery (Lee 
et  al., 2013). In this study, the choice of subjects could have 
been critical. Thirty-five healthy elderly women with mild cog-
nitive impairment (MCI) from a low socioeconomic background 
were recruited. Moreover, in this group the habitual intake of 
n-3 PUFAs was inadequate for financial reasons. These findings 
are in agreement with a double-blind, randomized control trial 
conducted by Sinn et al. (2012) in which 40 MCI subjects (over 
65 years old) with low fish intake were divided into 3 experi-
mental groups to receive a supplement rich in EPA (1.67 g EPA 
plus 0.16 g DHA), DHA (1.55 g DHA + 0.40 g EPA), or LA (2.2 g). 
After 6  months of n-3 PUFA supplementation, depressive 
symptoms, assessed by the Geriatric Depression Scale, ver-
bal fluency (Initial Letter Fluency), and self-reported physical 
health,were improved, especially in the DHA group. It is likely 
that MCI and low n-3 PUFA consumption offer the best pros-
pect of cognitive improvement. Interestingly, DHA seems to 
Table 3. n-3 PUFA Impact in Healthy Adults
Participants Treatment
Length  
of Trial Measurements Outcomes References
University students, 
mean age 
~22 years (n = 56, 
analyzed n = 54).
2.3 g/d fish oil (1.74 g EPA + 
0.25 g DHA) vs placebo 
(olive oil).
4 weeks. Mini International 
Neuropsychiatric 
Interview, neutral and 
emotional information 
processing tests.
No effects on attention, 
memory or reaction time of 
attention.
(Antypa et al., 
2009)
22–51 years (n = 33). 2.8 g/d fish oil (1.6 g EPA + 
0.8 g DHA).
35 days. Zimmermann and 
Fimm Attention Test 
procedure, EEG.
Improvements in sustained 
attention and reaction time 
of sustained attention.
(Fontani et al., 
2005)
18–35 years (n = 159, 
analyzed n = 140).
(1) DHA-rich fish oil (0.45 g 
DHA + 0.09 g EPA)/d;
(2) EPA-rich fish oil (0.2 g 
DHA + 0.3 g EPA)/d; 
(3) Placebo (olive oil).
12 weeks. Cognitive performance 
and mood battery test.
No treatments effects. (Jackson et al., 
2012a)
18–29 years (n = 65). (1) Low-dose DHA fish oil 
(0.45 g DHA + 0.09 g EPA)/
day; 
(2) High-dose DHA fish 
oil (0.9 g DHA + 0.18 g 
EPA)/d; 
(3) placebo (olive oil).
12 weeks. COMPASS, spatial 
working memory, 
numeric working 
memory, 3-back task, 
simple reaction time, 
Choice reaction time, 
Stroop task, RVIP.
Increased cerebral blood 
flow; cognitive tasks only 
assessed at end of study 
using comprehensive 
computerized cognitive test 
battery (episodic memory, 
working memory, attention, 
reaction time, executive 
function). Both dosages 
improved reaction times on 
2 attention tasks, but effects 
were lost when correcting 
for multiple testing.
(Jackson et al., 
2012b)
College students  
(mean age 
~20 ± 2 years) 
(n = 43, analyzed 
n = 41).
Fish oil (0.72 g EPA + 0.48 g 
DHA)/d vs placebo 
(coconut oil).
4 weeks. RAVLT, SCWT, TMT, 
PANAS.
No effects on verbal learning 
and memory, inhibition and 
executive control.
(Karr et al., 
2012)
Mildly depressed 
adults, 
18–70 years 
(average ± SD 
age 38 ± 14 years) 
(n = 218, analyzed 
n = 190).
Fish oil 1.5 g/d LC omega-3 
(0.85 g DHA + 0.63 g EPA) 
vs placebo (olive oil).
12 weeks. DASS, BDI, GHQ, STAXI-2. No treatment effects. (Rogers et al., 
2008)
18–45 years (n = 228, 
analyzed n = 176).
Fish oil (1.2 g DHA + 0.17 g 
EPA)/d vs placebo (high 
oleic acid sunflower oil).
6 months. Computerized cognitive 
test battery (episodic 
and working memory, 
attention, reaction 
time (RT) of episodic 
and working memory, 
and attention and 
processing speed).
Improvement in reaction 
times and working  
memory.
RBC DHA increased by 2.6%  
(to ~7.9%); RBC EPA  
increased by 0.2%  
(to ~0.81%).
(Stonehouse 
et al., 2013)
Abbreviations: BDI, Beck Depression Inventory; DAS, Differential Ability Scales; GHQ, General Health Questionnaire; PANAS, Positive and Negative Affect Schedule; 
RAVLT, Rey Auditory Verbal Learning Test; RBC, red blood cell; RVIP, Rapid Visual Information Processing; SCWT, Stroop Color Word Test; STAXI-2, State-Trait Anger 
Expression Inventory-2; TMT, treadmill test.
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Table 4. n-3 PUFA Impact on Mental Illnesses in Adulthood
Participants Treatment Length of Trial Measurements Outcomes References
18–70 years depressed 
(>15 on HDRS), 
medicated (n = 70).
Ethyl-EPA – 1, 2, or 
4 g/d or placebo.
12 weeks parallel 
design, adjunctive 
therapy.
HDRS,  
MADRS, BDI.
Treatment > placebo on all 
3 rating scales with 1 g/d 
EPA – strong effects for 
core depressive symptoms. 
Treatment = placebo on 2 g 
and 4 g/d (nonsignificant 
trends).
(Peet and 
Horrobin, 2002)
28–73 years diagnosed 
MDD (85% women) 
HDRS score > 18 
(n = 20).
2g ethyl-EPA (96% 
from fish oil) or 
placebo, Vit E.
4 weeks parallel 
design, adjunctive 
therapy.
HDRS. Treatment > placebo at weeks 
2, 3, and 4 on HDRS score 
and on core depressive 
symptom subscales.
(Nemets et al., 
2002)
18–60 years outpatients 
with MDD; 
HDRS score > 18, 
medicated, (n = 22).
3.3 g/d n-3 PUFA (2.2 g 
DHA, 1.1 g EPA).
8 weeks parallel 
design, adjunctive 
therapy.
HDRS. Treatment > placebo on 
HDRS.
(Su et al., 2003)
18–65 years MDD 
diagnosis; HDRS 
score > 16 (80% 
female) (n = 35).
2 g/d DHA or placebo. 6 weeks parallel. MADRS,  
HDRS, GAFS.
Treatment = placebo on 
outcome measures.
(Marangell et al., 
2003)
18–65 years recruited, 
(mean age 38), 
treated for current 
depressive episode 
(53% female) (n =77).
3 g/d n-3 PUFA (2.4 g 
DHA; 0.6 g EPA) + 
Vit E or olive oil 
placebo.
12 weeks parallel, 
adjunctive 
therapy.
HDRS short  
form, BDI.
Treatment = placebo on 
outcome measures 
(improvements in both 
groups at week 2).
(Silvers et al., 
2005)
18–72 years outpatients 
with major 
depression diagnosis 
(n = 83, 45 males).
3 g/d n-3 PUFA (2.2 g 
DHA, 0.6 g EPA) + 
Vit E or olive oil 
placebo.
4 month parallel 
design, adjunctive 
therapy.
HDRS, BDI, GAFS. Treatment = placebo on 
outcome measures 
(improvements in both 
groups).
(Grenyer et al., 
2007)
18–40 years with MDD 
during pregnancy 
(n = 24).
2.2 g EPA + 1.2 g DHA 
or placebo, both 
with tocopherols 
and orange flavor.
8 weeks, parallel 
design.
HDRS, EPDS, GDI. Treatment > placebo on 
outcome measures.
(Su et al., 2008)
18–70 years recruited, 
(mean age = 38); 
people from GP 
surgeries or public 
with mild-moderate 
depression (77% 
female) (n = 190).
630 mg EPA, 850 mg 
DHA, 870 mg olive 
oil, or olive oil 
placebo (both with 
tocopherols and 
orange oil).
12 weeks parallel 
design.
DASS, BDI, STAEI, 
mood using 
diary and 
visual probe 
task, cognitive 
function.
Treatment = placebo on 
outcome measures 
(improvements in both 
groups).
(Rogers et al., 
2008)
40–55 years recruited, 
(mean age 
49) postmenopausal 
women with 
psychological distress 
and depressive 
symptoms (n = 120).
1.5 g ethyl-EPA, 0.5 g 
ethyl-DHA.
8 weeks parallel 
design.
PGWB, 
HSCL-D-20, 
HDRS.
Treatment = placebo on all 
measures (improvements in 
both groups). Treatment > 
placebo in women without 
MDE (major depressive 
episode diagnosis).
(Lucas et al., 
2009)
Major depression 
+ coronary heart 
disease (n = 122).
930 mg ethyl-EPA + 
750 mg ethyl DHA/d 
or corn oil placebo.
10 weeks parallel 
design, adjunctive 
therapy.
BDI-II, HDRS. Treatment = placebo on 
outcome measures 
(improvements in both 
groups).
(Carney et al., 
2009)
18–65 years inpatients 
with bipolar disorder 
(n = 30).
9.6 g/d n-3 PUFA (6.2 g 
EPA, 3.4 g DHA) 
or olive oil esther 
placebo.
4 month parallel 
design; 
adjunctive 
therapy.
HDRS, YMRS, 
CGI-S, GAS.
Treatment > placebo on 
GAS, HDRS and CGI; 
treatment = placebo on 
YMRS.
(Stoll et al., 1999)
57 Bipolar depressed 
and 59 rapid cycling 
(mean age 45) 
(n = 116, 51% male).
6 g/d ethyl-EPA or 
liquid paraffin 
placebo.
4 month parallel 
design; 
adjunctive 
therapy.
IDS, YMRS, CGI- 
BP (bipolar 
disorder).
Treatment = placebo on 
outcome measures.
(Keck et al., 2006)
Outpatients with 
bipolar depression + 
scores > 17 on HDRS, 
(mean age 47) (n = 75, 
76% female).
1 g/d ethyl EPA 
(n = 24); 2 g/d ethyl 
EPA (n = 25) or 
paraffin placebo.
12 week parallel 
design, adjunctive 
therapy.
HDRS, YMRS,  
CGI.
Treatment > placebo on  
HDRS & CGI on 1 g and 
2 g/d. Treatment = placebo 
on YMRS.
(Frangou et al., 
2007)
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Participants Treatment Length of Trial Measurements Outcomes References
16–64 years presenting 
after act of repeated 
self-harm (n = 49, 
65% women).
1.2 g/d EPA + 0.9 g DHA 
or corn oil placebo 
(with 1% EPA/DHA).
12 weeks parallel 
design in addition 
to standard care.
BDI, HDRS, 
OAS-M, IMT/ 
DMT, PSS, 
DHUS.
Treatment > placebo on 
BDI, HDRS, PSS, DHUS. 
Treatment = placebo on 
OAS-M and IMT/DMT 
(hostility/aggression, 
memory).
(Hallahan et al., 
2007)
Study 1: schizophrenic 
patients, PANSS score 
> 40, mean age 44 
(n = 45).
Study 2: diagnosed 
schizophrenia, 
untreated, mean age 
35, (n = 30).
2 g/d EPA or corn oil 
placebo.
3 months parallel, 
single therapy 
unless drugs 
needed.
PANSS; need for 
antipsychotic 
medication.
Treatment > placebo, 
particularly on positive 
subscale; 12/12 placebo 
and 8/14 EPA patients took 
medication.
(Peet et al., 2001)
(18–65 years, M = 40; 
61% male) diagnosed 
schizophrenia or 
schizoaffective 
disorder (n = 30).
3 g/d ethyl EPA + Vit E 
or mineral oil + Vit E 
placebo.
16 weeks parallel 
design, adjunctive 
therapy.
PANSS, CGI, 
MADRS, RBANS, 
AIMS, SARS.
Treatment = placebo on 
outcome measures (some 
showed improvements in 
both groups).
(Fenton et al., 
2001)
18–55 years 
schizophrenic, 
treatment resistant 
patients, PANSS score 
> 10 (n = 40, mean 
age 45).
3 g/d ethyl-EPA or 
liquid paraffin 
placebo.
12 weeks parallel 
design, adjunctive 
therapy.
PANSS, ESRS. Treatment > placebo on 
PANSS and dyskinesia 
subscale of ESRS. 
Treatment = placebo on 
other ESRS subscales.
(Emsley et al., 
2002)
 20–62 years treatment- 
resistant 
schizophrenia; PANSS 
> 50, (n = 115, mean 
age 37, 66% male).
1, 2, or 4 g/d ethyl- 
EPA or liquid 
paraffin placebo.
12 weeks parallel 
design, adjunctive 
therapy.
PANSS, LUNSERS, 
MADRS, AIMS, 
BAS, SARS.
Treatment = placebo on all 
rating scales; 2 g treatment 
> placebo for patients on 
clozapine (associated with 
↑AA).
(Peet et al., 2002)
First-episode psychosis 
patients (n = 69, mean 
age 21, 76% male).
2 g/d ethyl-EPA or 
mineral oil placebo 
not absorbed by 
intestinal tract 
(both with Vit E).
12 weeks parallel 
design, adjunctive 
therapy.
BPRS, SANS, 
CDSS, CGI, GAF, 
SOFAS.
Treatment = placebo on all 
outcome measures.
Treatment > placebo on CGI 
co-varying for duration 
of untreated psychosis; 
treatment > placebo at 
weeks 4–6.
(Berger et al., 
2007)
13–25 years met defined 
risk factors for 
psychosis (n = 81, mean 
age 16, 40% male).
1.2 g/d n-3 PUFAs 0.7 g 
EPA, 0.48 g DHA, and 
7.6 mg of vitamin E).
12 weeks. PANSS, MADRS, 
GAF.
Treatment > placebo on 
PANSS and GAF at 12 
weeks, 6 and 12 months.
(Amminger et al., 
2010)
19–30 years university 
students (study 
measured aggression 
and executive 
function) (n= 41, 70% 
female).
1.5–1.8 g/d DHA or 
97% soybean oil + 
3% fish oil placebo 
capsules.
3 months  
parallel  
design.
P-F Study; Stroop; 
Dementia- 
detecting test.
Treatment > placebo on 
aggression (increased in 
placebo group during exam 
time); treatment = placebo 
on other measures.
(Hamazaki et al., 
1996)
18–40 years females 
with moderately 
severe borderline 
personality disorder 
(n= 30, mean age 26).
1 g/d ethyl-EPA or 
mineral oil placebo.
8 weeks parallel 
design.
OAS-M; MADRS. Treatment > placebo 
aggression and depressive 
symptoms
(Zanarini and 
Frankenburg, 
2003)
MDD patients (n= 154). (1) EPA 1 g/d;
(2) DHA 1 g/d;
(3) Placebo.
8 weeks. HDRS-17, QIDS- 
SR-16, CGI-S.
Treatments and placebo 
improved HDRS-17, QIDS- 
SR-16, CGI-S.
(Mischoulon 
et al., 2015)
Abbreviations: AIMS, Abnormal Involuntary Movement Scale; BDI, Beck Depression Inventory; BPRS, Brief Psychiatric Rating Scale; CBC, Child Behav-
iour Checklist; CDSS, Calgary Depression Scale for Schizophrenia; CGI-S, Clinical Global Impression-Severity; DASS, Depression & Anxiety Stress Scale; 
DHUS, Daily Hassles & Uplifts Scale; DMT, Delayed Memory Task; ESRS, Extrapyramidal Symptom Rating Scale; GAFS, Global Assessment of Function-
ing Scale (revised GAS); GAS, Global Assessment Scale; HDRS, Hamilton Depression Rating Scale; HSCL-D-20, 20-item Hopkins Symptom Checklist 
Depression Scale; IDS, Inventory for Depressive Symptomology; IMT, Immediate Memory Task; LUNSERS, Liverpool University Neuroleptic Side-Effects 
Rating Scale; MADRS, Montgomery-Asberg Depression Rating Scale; MDD, major depressive disorder; OAS-M, The Overt Aggression Scale, Modified; 
PANSS, Positive and Negative Syndrome Scale; PGWB, Psychological General Well-Being Schedule; PSS, Perceived Stress Scale; RBANS, Repeatable Bat-
tery for the Assessment of Neuropsychological Status; SANS, Scale for the Assessment of Negative Symptoms; SARS, Simpson-Angus Rating Scale; 
SOFAS, Social and Occupational Functioning Assessment Scale; STAEI, State-Trait Anger Expression Inventory; YMRS, Young Mania Rating Scale.
Table 4. Continued
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Table 5. n-3 PUFA Impact in Healthy Elderly
Participants Treatment
Length  
of Trial Measurements Outcomes References
70–75 years, 
cognitively 
healthy, MMSE ≥ 
24 (median = 29) 
(n = 867, analysis 
on n =748).
Ethyl ester fish oil 
(0.2 g EPA + 0.5 g 
DHA)/d vs placebo 
(olive oil).
24 months. CVLT. No effect on global 
cognitive function, 
memory, processing 
speed, executive 
function, global delay 
score.
(Dangour et al., 
2010)
60–80 years, stable 
MI patients, 
MMSE >21 
(average ± SD 
28 ± 1.6 points).
(1) 0.4 g/d EPA + DHA; 
(2) 2 g/d ALA; (3) EPA 
+ DHA + ALA; (4) 
Placebo.
40 months. MMSE. No effect on MMSE. (Geleijnse et al., 
2012)
60–80 years, healthy 
women (n = 57, 
analyzed n = 49).
(1) 0.8 g/d DHA (algal 
oil); (2) 12 mg/d 
lutein; (3) DHA + 
lutein; (4) Placebo.
4 months. Cognitive 
test battery 
measuring 
verbal fluency, 
memory, 
processing speed 
and accuracy.
Treatments (1), (2), (3) 
improved verbal 
fluency. DHA + lutein 
improved rate of 
learning and memory 
in 1 of 6 recall tests.
(Johnson et al., 
2008)
≥60 years, MCI, 
MMSE = 26.4 
(25–28), middle to 
low- 
socioeconomic 
status (n = 36, 
analyzed n = 35).
Fish oil (1.3 g DHA 
+ 0.45 g EPA)/d vs 
placebo (corn oil).
12 months. MMSE, RAVLT. Improved memory 
(short-term memory, 
working memory, 
immediate visual 
memory, delayed 
recall).
(Lee et al., 2013)
51–72 years, healthy 
(n = 44, analyzed 
n = 38.
Fish oil (1.05 g DHA 
+ 1.50 g EPA)/d vs 
placebo.
5 weeks. Working memory. Improved working 
memory. TNF-α 
inversely related to 
working memory 
performance.
(Nilsson et al., 
2012)
>65 years, MCI, 
MMSE ≥ 22 
(average ~27 ± 2.5) 
(n = 50).
(1) EPA-rich fish oil 
(1.67 g EPA + 0.16 g 
DHA)/d); (2) DHA- 
rich fish oil: (1.55 g 
DHA + 0.40 g 
EPA)/d; (3) Placebo 
(safflower oil).
6 months. Cognitive battery. DHA improved verbal 
fluency (test of fluid 
thinking/semantic 
memory). Only 
1 of 11 cognitive 
assessments affected.
(Sinn et al., 2012)
45–77 years (average 
~56 ± 8.7 years), 
healthy (n = 112, 
analyzed n = 75).
Tuna oil (0.25 g DHA 
+ 0.06 g EPA)/d vs 
placebo (soybean 
oil).
90 days. CDR, visual acuity. No treatment effects. (Stough et al., 
2012)
≥65 years, 
cognitively 
healthy, median 
(25, 75 percentile) 
MMSE = 28, 
ranged from 23 to 
30 (n = 302).
(1) Low-dose fish oil 
(0.26 g EPA + 0.18 g 
DHA)/d; (2) High 
dose fish oil (1.09 g 
EPA + 0.85 g DHA)/d; 
(3) Placebo (oleic 
acid).
26 weeks. Cognitive test 
battery.
Treatment improved 
attention in APOE4 
allele carriers. 
Treatment–gender 
interactions: 
Attention improved 
in men.
(van de Rest 
et al., 2008a)
50–90 years, 
nondemented 
participants 
with memory 
complaints, MMSE 
≥ 27 (average 
~28.5 ± 1.11) 
(n = 157, analyzed 
n = 122).
PS containing LC 
omega-3: 300 mg 
PS + 0.08 g (DHA + 
EPA)/d.
15 weeks. Immediate and 
delayed verbal 
recall, learning 
abilities, and 
time to copy 
complex figure.
Improved verbal 
immediate recall. 
A subset of 
participants with 
higher baseline 
cognitive status 
performed better 
on immediate and 
delayed verbal recall, 
learning abilities 
and time to copy a 
complex figure.
(Vakhapova et al., 
2010)
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be more of benefit in both memory and cognition than EPA, 
or their combination, as observed in adulthood. This discrep-
ancy could be due to the phospholipid degradation occurring at 
this last stage of life. Since DHA constitutes the most abundant 
fatty acid in the brain and due to its importance in the forma-
tion and functionality of the CNS, it is plausible to think that 
DHA can ameliorate cognitive performance more than other 
PUFAs in older subjects.
n-3 PUFAs and Alzheimer’s Disease
Postmortem analysis of AD subjects shows lower n-3 PUFAs 
levels in the hippocampus and frontal lobe together with 
decreased hippocampal size (Soderberg et al., 1991; Yehuda 
et al., 2002). Moreover, reduced risk of senile dementia and 
AD has been reported to be related to higher fish consump-
tion (Morris et  al., 2003). However, no cognitive improve-
ments were observed in subjects affected by moderate AD 
after 24 weeks of n-3 PUFAs (EPA 1080 mg plus DHA 720 mg) 
(Chiu et  al., 2008). Neither has a longer trial, up to 1  year 
of n-3 PUFA supplementation, shown neuropsychiatric 
improvements in AD subjects (Freund-Levi et al., 2008). On 
the other hand, Yehuda et  al. (1996) have shown improve-
ments in mood, cooperation, appetite, sleep, ability to 
navigate in the home, and short-term memory after only 4 
weeks of an ALA:LA mixture (1:4). Furthermore, within 174 
AD subjects that underwent n-3 PUFA administration for a 
total period of 1  year, only 15% of them showed reduction 
in cognitive decline (Freund-Levi et  al., 2006). The impact 
of n-3 PUFAs on mental illnesses in elderly are reported in 
Table 6.
n-3 PUFAs: Mechanisms of Action
Inflammation
As outlined in the previous sections, n-3 PUFAs have multiple 
implications in several conditions. Therefore, they are likely to 
act via multiple mechanisms (Figure 2). The antiinflammatory 
effect exerted by n-3 PUFAs represents one of the most inves-
tigated mechanisms. Moreover, chronic inflammation is now 
considered to be central to the pathogenesis of stress-related 
disorders such as depression (Barnes et  al., 2016). Primarily 
EPA and in part DHA metabolize into antiinflammatory com-
pounds such as leukotrienes (5 series), prostaglandins (3 series), 
resolvins, lipoxins, and neuroprotectin D1. Competing with n-6 
PUFAs for metabolism, both EPA and DHA may interfere with 
the production of the n-6 PUFA arachidonic acid-derived pro-
inflammatory eicosanoids such as prostaglandins (series 2), 
leukotrienes (series 4), and thromboxanes (series 2) (Das, 2006). 
DHA and EPA have been also shown to inhibit the release of pro-
inflammatory cytokines, such as interferon-γ, tumour necrosis 
factor-α, IL-1β, IL-2, and IL-6, directly acting on the transcrip-
tional factor NF-kB (Kang and Weylandt, 2008).
HPA Axis
n-3 PUFAs seem to play a role in the regulation of the stress-
response influencing the activity of the HPA axis. It has been 
proposed that n-3 PUFA deficiency may induce a chronic stress 
state by disruption of glucocorticoid receptors (GR)-mediated 
negative feedback (Larrieu et  al., 2014, 2016). Controversially, 
the same authors observed that supplementation of n-3 
PUFAs (9 weeks) prevented detrimental chronic social defeat 
Participants Treatment
Length  
of Trial Measurements Outcomes References
50–75 years, MMSE 
< 26 (average 
~29 ± 1.0, ranged 
from 26 to 
30) (n = 80, z 
n = 65).
Fish oil 2.2 g/d LC 
omega-3 (1.32 g EPA 
+ 0.88 g DHA) vs 
placebo (sunflower 
oil).
26 weeks. Stroop Color- 
Word test, TMT, 
AVLT.
Improved executive 
function. Subset who 
showed greatest 
increase in n-3 index 
showed improved 
memory. Improved 
white matter 
microstructural 
integrity, grey matter 
volume in frontal, 
temporal, parietal 
and limbic areas. 
Improvements in 
executive function 
associated with 
peripheral BDNF and 
inversely with fasting 
insulin.
(Witte et al., 2014)
≥55 years (average 
~70 ± 9 years), 
subjective 
memory 
complaints with 
ARCD, MMSE >26 
(n = 485).
0.9 g/d DHA from algal 
oil vs placebo (corn 
+ soy oil).
24 weeks. CANTAB PAL, 
MMSE.
Improved visuospatial 
learning and episodic 
memory, immediate 
and delayed verbal 
recognition memory.
(Witte et al., 2014)
Abbreviations: AVLT, Auditory Verbal Learning Test; CANTAB-PAL, Cambridge Neuropsychological Test Automated Battery - Paired Associates Learning; CDR, Clinical 
Dementia Rating; CVLT, California Verbal Learning Test; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; RAVLT, Rey Auditory Verbal Learning 
Test; TNF- α, tumour necrosis factor-α.
Table 5. Continued
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Table 6. n-3 PUFA Impact on Mental Illnesses in Elderly
Participants Treatment Length of Trial Measurements Outcomes References
>65 years 
nondepressed 
community 
dwelling adults 
(n = 302, mean age 
70, 55% male).
1.8 g/d EPA + DHA, 
400 mg/d EPA + 
DHA.
26 weeks. CES-D, MADRS, 
GDS-15,
HADQ.
Treatment = placebo on 
outcome measures.
(van de Rest et al., 
2008b)
People with AD living 
in own homes, on 
stable treatment 
with acetylcholine 
esterase inhibitors, 
(n = 204, mean age 
73).
1.72g DHA + 
600mg EPA/ 
day.
6 months parallel + 
1-way crossover 
to fish oil for 
6 months.
NPI, MADRS, CGB, 
DAD.
Treatment > placebo on 
MADRS in non- 
apoE-4 carriers and 
agitation in apoE-4 
carriers.
(Freund-Levi et al., 
2008)
50–73 years AD 
patients, (n = 100, 
21% females).
0.5 g ALA:LA, 1:4 
ratio.
4 weeks, adjunctive 
therapy.
12-item quality of 
life questionnaire 
(caregiver), 
clinician 
interview.
Treatment > placebo 
on 12-item QOL 
questionnaire.
(Yehuda et al., 1996)
Nursing home 
residents with 
mild-moderate 
vascular dementia 
(n = 20, mean age 
83).
4.32 g/d DHA. 12 months. MMSE; HDS-R; 
clinical 
evaluation.
Treatment > placebo on 
outcome measures 
after 3 and 6 months, 
associated with DHA 
increases.
(Terano et al., 1999)
n = 21, mean  
age 68; 57% male.
240 mg/d AA+DHA 
or olive oil 
placebo.
3 months. RBANS (Japanese 
version).
Treatment > placebo on 
immediate memory 
and attention.
(Kotani et al., 2006)
n = 178, mean  
age 74.
1.72 g DHA + 
600 mg EPA/d.
6 months, 
adjunctive 
therapy.
MMSE, ADAS-cog; 
global function 
on bCDRS.
Treatment > placebo on 
MMSE in mild MCI 
group (n = 27).
(Freund-Levi et al., 
2006)
n = 35, mean  
age 74, 57%  
female.
1.08g EPA + .72 g 
DHA or olive oil 
placebo.
6 months. CIBIC-plus; ADAS- 
cog; MMSE; HDRS.
Treatment > placebo on 
CIBIC-plus. Treatment 
> placebo on ADAS- 
cog in MCI sub-group.
(Chiu et al., 2008)
n = 302 (mean  
age 70, 55% male.
1.8 g/d EPA+DHA; 
400 mg/d EPA + 
DHA.
26 weeks. Word Learning Task; 
Digit Span; Trail 
Making; Stroop; 
Verbal Fluency.
Treatment = placebo on 
outcome measures; 
treatment > placebo on 
attention for apoE- 
4 carriers and males.
(van de Rest et al., 
2008a)
Abbreviations: ADAS-cog, cognitive portion of the Alzheimer’s Disease Assessment Scale; CES-D, Centre for Epidemiologic Studies Depression Scale; CGB, Caregivers 
Burden Scale; CIBIC-plus, Clinician’s Interview-Based Impression of Change Scale; DAD, Disability Assessment for Dementia scale; GDS, Geriatric Depression Scale; 
HADQ, Hospital Anxiety and Depression Questionnaire; HDRS, Hamilton Depression Rating Scale; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric 
Inventory; RBANS, Repeatable Battery for the Assessment of Neuropsychological Status.
Figure 2. Omega-3 polyunsaturated fatty acid [(n-3) PUFA] mechanisms of action. Schematic representing the possible mechanisms of action of n-3 PUFAs.
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stress-induced emotional and neuronal impairments by attenu-
ating HPA dysfunction (Larrieu et al., 2014). Similarly, n-3 PUFA 
(EPA 12%, DHA 18%; 16 weeks) supplementation decreased 
stress-induced high plasma corticosterone levels and decreased 
anxiety- and depressive-like behaviors, as assessed by the 
elevated plus maze and the forced swim test, while increas-
ing cognition as assessed by the Morris water maze in rats that 
underwent restrain stress (Ferraz et  al., 2011). Accordingly, a 
study from our laboratory recently revealed n-3 PUFA (EPA 80%, 
DHA 20%; 12 weeks)-induced hippocampal GR activation cor-
related with cognitive and mood state improvements in adult 
female rats assessed by the novel object recognition, elevated 
plus maze, and forced swim test (Pusceddu et al., 2015b) (Table 7). 
Another study from our laboratory showed the protective effects 
of DHA against corticosterone-induced neuronal death as well 
as astrocyte overgrowth in cortical primary cultures (Pusceddu 
et al., 2015c). Furthermore, in the same study, we observed that 
the DHA was able to reverse the corticosterone-induced down-
regulation of GR expression levels in neurons. The regulation of 
GRs may represent a novel mechanism exerted by n-3 PUFAs 
which is worth to investigate further.
BDNF
DHA regulation of BDNF protein levels has gotten the attention 
of several researchers. This is of importance, since stress-related 
pathologies are strongly associated with decreased levels of 
BDNF (Lee and Kim, 2010). Accordingly, decreased BDNF levels 
are found in rats fed a diet containing inadequate n-3 PUFAs 
(Rao et  al., 2007). Indeed, DHA supplementation to cortical 
astrocytes cells increased cAMP response element-binding pro-
tein and BDNF protein levels via a p38 mitogen-activated pro-
tein kinase-dependent mechanism (Rao et al., 2007). Likewise, 
DHA-induced hippocampal calcium–calmodulin protein kinase 
II-cAMP response element-binding protein-BDNF pathway acti-
vation enhanced synaptic plasticity, memory, and learning in 
rats (Wu et al., 2008).
Monoaminergic System
Associations between monoaminergic dysfunction in stress-
related pathologies and lower dietary levels of n-3 PUFAs have 
been observed. Male rats with a 61% decrease in brain DHA, 
induced by feeding a diet deficient in n-3 PUFAs from birth, 
exhibited lower expression of the serotonin-synthesizing 
enzyme tryptophan hydroxylase in the midbrain and higher ser-
otonin turnover in the prefrontal cortex compared with controls 
(McNamara et al., 2010b). Controversially, feeding a diet contain-
ing ALA reversed the effect on serotonin turnover (McNamara 
et al., 2010b). Consistent with this, adult rats supplemented with 
DHA and EPA exhibited increased concentrations of serotonin in 
the frontal cortex and hippocampus (Vines et al., 2012). Similarly, 
in mice, the decrease in brain serotonin levels induced by unpre-
dictable chronic mild stress was reversed by an n-3 PUFA diet 
supplementation (Vancassel et al., 2008). Likewise, the role of n-3 
PUFAs in modulation of noradrenergic neurotransmission has 
recently received attention. Studies in cultured SH-SY5Y neu-
roblastoma cells suggest that either brief exposure to, or incor-
poration of, DHA increased basal, but not KCl-evoked release 
of [3H]- norepinephrine by a mechanism involving enhanced 
exocytosis (Mathieu et al., 2010). DHA treatment also increased 
the density of β-receptors on rat astrocytes in primary culture 
(Joardar et al., 2006). Also, the DA system is affected by variation 
in dietary n-3 PUFA content. Virgin females with lower tissue 
DHA levels had altered abundancy of D1 and D2 DA receptors in 
the caudate nucleus relative to virgin females with normal DHA 
(Davis et al., 2010). These receptor alterations have been found 
in rodent models of depression and are consistent with the pro-
posed hypodopaminergic basis for anhedonia and motivational 
deficits in depression (Kram et al., 2002). The effects of n-3 PUFAs 
on adult rodents’ behavior are reported in Table 7.
Glutamatergic System
It has been observed that n-3 PUFAs can regulate the func-
tionality of the glutamatergic system, which can undergo dys-
regulation during aging. Indeed, n-3 PUFAs are involved in the 
regulation of the post-synaptic 2-amino-3-propionic acid and 
N-methyl-d-aspartate receptors (Nishikawa et  al., 1994). This 
suggests that n-3 PUFAs may play an important role in the gen-
esis of long-term potentiation, which is involved in memory for-
mation and restoration of synaptic plasticity (Dyall et al., 2007; 
Lynch et al., 2007; Kelly et al., 2011). Excess glutamate can lead 
to excessive release of AA, which initiates a proinflammatory 
cascade of events involving the production of eicosanoids via 
the activation of inducible cyclooxigenase and lipoxigenases 
and the production of proinflammatory cytokines (Bazan, 2007; 
Farooqui et al., 2007).
Aβ Oligomers and Antiapoptosis
In vitro studies have shown DHA preventive effects against Aβ 
oligomer-induced neurotoxicity both in cortical and hippocam-
pal cultures (Florent et  al., 2006; Wang et  al., 2010). Moreover, 
DHA has been found to promote cellular survival and prevent 
cortical neuronal apoptosis in primary cultures in a physiologi-
cal condition (Cao et al., 2005) and after chronic corticosterone 
treatment (Pusceddu et  al., 2015c). Moreover, similar results 
have been found in animal models of AD fed with n-3 PUFA-
enriched diet (Lim et al., 2005a; Green et al., 2007). Interestingly, 
learning memory performance improved in Aβ-infused adult 
rats supplemented upon DHA intervention (Hashimoto et  al., 
2002; Hashimoto et al., 2005, 2009) (Table 8). These findings indi-
cate that n-3 PUFAs decrease Aβ levels and have antioxidative 
stress and antiapoptosis effects, leading to neuron protection 
and maintenance of learning memory ability.
New Horizons: The Gut Microbiome
Parallel with these findings, we recently shed light on the role of 
n-3 PUFAs in regulating the gut microbiome, which is involved 
in a bidirectional communication with and influence over the 
brain both in rodents and humans (Cryan and Dinan, 2012). 
Indeed, there is a corpus of evidence to support the view that 
the gut microbiome plays an important role in stress-related 
psychopathologies such as depression (Dinan and Cryan, 2016). 
A first study conducted in our laboratory showed that EPA/DHA 
combination (1 g/kg/d) was able to normalize early-life stress-
induced disruption of female rat gut microbiome (Pusceddu 
et al., 2015a). This microbial disruption seems to be mainly due 
to a shift in Bacteroidetes:Firmicutes, the alteration of which 
in human stool specimen has been revealed in depressed indi-
viduals (Jiang et al., 2015). The early-life stress-induced micro-
bial disruption also altered abundance of members of the gut 
microbiome known to have inflammatory effects such as 
Akkermansia (Stecher et al., 2007) and Flexibacter (Frank et al., 
2007), and this was correlated with alteration of the corticoster-
one response to acute stress. Notably, EPA/DHA administration 
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Table 7. Effect of n-3 PUFAs on Adult Rodent Behavior
Animals Treatment Length of Treatment Measurements Outcomes References
C57Bl6/J 
mice 2nd 
generation.
(1) control;
(2) n-3 def diet;
(3) n-3 suppl diet.
3 months old. Chronic social defeat 
test, open field, 
forced swim test.
(3) ameliorated 
chronic 
social defeat 
stress-induced 
emotional 
and neuronal 
impairments 
by impeding 
HPA axis 
hyperactivity.
(Larrieu et al., 
2014)
C57BL6/J 
female 
mice.
(1) n-3 def diet;
(2) n-3 suppl diet.
After weaning, both 
groups were fed 
with a control diet.
Social investigation, 
forced swim test, 
open field.
Anxiety-like 
behaviour 
induced by (1) 
was abolished 
by the 
cannabinoid 
agonist 
WIN55,212-2.
(Larrieu et al., 
2012)
C57Bl/6 mice. (1) control;
(2) n-3 def diet + (1) after 
weaning.
Until 14 weeks old. Open-field, object 
recognition, light-
dark transition, 
elevated plus maze, 
social interaction 
tests.
(2) reduced 
anxiety-like 
behavior 
compared to (1).
(Palsdottir et al., 
2012)
Wistar 
rats 2nd 
generation.
(1) n-3 adeq diet;
(2) n-3 def diet.
Until 60 days old. Inhibitor avoidance 
task, flinch-jump 
task, open-field, 
elevated plus maze.
(1) Improved 
inhibitor 
avoidance task 
and elevated 
plus maze 
performances 
compared to (2).
(Moreira et al., 
2010)
Long Evans 
rats.
3 generations (F):
(1) n-3 adeq diet;
(2) n-3 def diet;
(3) n-3 def till birth of 3F;
(4) n-3 def till weaning of 3F;
(5) n-3 def till 7 weeks of 3F.
Until 9 or 13 weeks 
of age.
MWM, motor activity. (3), (4) similar 
MWM 
outcomes and 
DHA brain 
levels to (1).
(Moriguchi and 
Salem, 2003)
Wistar 
rats, 2nd 
generation.
(1) Control;
(2) n-3 def diet;
(3) same as (2) + DHA/AA 
at weaning.
After lactation all 
groups received (1).
Passive-avoidance 
test.
(3) reversed 
learning 
impairments 
observed in (2).
(Garcia- 
Calatayud 
et al., 2005)
Wistar 
Imamichi 
rats, 2nd 
generation.
(1) Control;
(2) n-3 def diet;
(3) same as (2) + DHA 
(300mg/kg/d).
DHA was 
administrated 
1 week prior 
behavioral test.
Elevated plus maze, 
fear conditioning.
(3) reversed 
behavioral 
impairments 
observed in (2).
(Takeuchi et al., 
2003)
Wistar 
rats, 2nd 
generation.
(1) Control;
(2) fish oil.
2 months. Elevated plus maze, 
ambulatory activity 
test.
(2) improved 
animal 
behaviors.
(Chalon et al., 
1998)
Long Evans 
rats.
(1) def diet;
(2) adeq diet.
15 weeks. Forced swim test, 
resident intruder 
test, open field.
(2) Improved 
forced swim 
and resident 
intruder test.
(DeMar et al., 
2006)
Long Evans 
rats.
(1) Control;
(2) artificial rearing: n-3 
def diet;
(3) artificial rearing: n-3 
adeq diet.
Until 9 weeks. Motor activity, 
elevated plus- 
maze, Morris water 
maze.
(3) Improved 
spatial learning 
compared to (2).
(Lim et al., 2005b)
Long Evans 
rats.
(1) Control;
(2) n-3 def diet;
(3) same as (2) + DHA 
enriched diet after 
weaning.
56 days. Locomotor activity, 
thermal stimulus.
(3) reversed 
behavioral 
impairment 
compared to (2).
(Levant et al., 
2004)
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was beneficial for restoring members of the gut microbiome with 
immunoregulatory functions, suggesting a possible prevention 
to an overly robust stress-induced inflammatory response that 
may contribute to the onset of mental illnesses. Subsequent 
to this first evidence, a second study revealed a correlation 
between neurobehavioral outcomes and gut microbiome com-
position in mice fed with diets containing altered n-3 PUFA sta-
tus (Robertson et al., 2016). Although the impact of n-3 PUFAs 
Table 8. Effect of n-3 PUFAs in Aged Rodents
Animals Treatment
Length of  
Treatment Measurements Outcomes References
C57BL/6 mice. (1) n-3: n-6 = 1: 29 ratio;
(2) n-3: n-6 = 1: 3.6 ratio;
(3) n-3: n-6 = 2: 1 ratio.
From age 3  
to 7 months.
Open field,
Barnes maze;
Serum and hippocampal 
cytokines;
Hippocampal Ki67, DCX, 
GFAP, IBA-1, oxo8dG/
oxo8G staining.
(3) ↑ Anxiety, hippocampal 
dependent spatial 
memory vs (1);
(3) ↑ hippocampal PUFA, 
↓ hippocampal and 
serum TNF-α, ↑ KI67 and 
DCX vs (1);
(Grundy et al., 
2014)
C57B6/J mice. Gavage:
(1) n-3 PUFA mixture 
(440 mg/kg);
(2) olive oil;
(3) Control.
From 19 to  
27 months.
MWM, NOR, SYM, CFC, 
EPM;
BrdU, DCX, GFAP, Ki67, 
Iba-1;
DG, CA1, CA3 volume, 
cell numbers, 
neurons, dendrites.
(1) ↑ NOR, MWM, SYM, 
CFC;
(1) ↑ neurogenesis, 
dendritic arborization 
of DG newborn neurons, 
hippocampal volumes 
and cell density, 
microglia.
(1) ↓ apoptosis, 
astrocytosis.
(Cutuli et al., 
2014)
Sprague-Dawley 
rats.
Gavage:
(1) Control
(2) Control + fish oil;
(3) Deficient;
(4) Deficient + fish oil.
Max 140 days. MWM. (3) ↓ MWM performance;
(4) partially ↑ MWM;
(2) ↑ MWM.
(Chung et al., 
2008)
SAMP8 
mice 2nd 
generation.
(1) n-3 def diet;
(2) n-3 enriched diet.
Until 28  
weeks old.
Sidman active avoidance 
task, light and dark 
discrimination 
learning test.
(2) ↑ Performance in  
discrimination  
learning test.
(Umezawa 
et al., 1995)
Wistar rats. (1) control;
(2) DPA or EPA enriched 
diet.
56 days. Morris water maze;
LTP, caspase-3, 
microglial activity.
(2) ↑ Spatial learning, ↓ 
microglial activation.
(Kelly et al., 
2011)
C57B6/J mice. (1) control;
(2) DHA enriched diet.
(3) n-3 def diet + DHA 
enriched at age 
8 months.
Entire  
lifespan.
Open field, light/dark 
test, Morris water 
maze
(2) ↑ Anxiety-like  
behavior and memory  
compared to (3).
(Carrie et al., 
2002)
CD1 mice 2nd 
generation.
(1) n-3 def diet;
(2) n-3 enriched diet.
Until 
23 months.
Forced swim test, 
Y-maze test, 
cytokines.
(2) ↓ Depressive-like 
behavior.
(Moranis et al., 
2012)
Wistar rats 3rd 
generation.
(1) n-3 def diet;
(2) n-3 def diet + oral 
DHA for 10 weeks prior 
behavior.
10 weeks. 8-arm radial maze (2) ↑ Memory  
compared to (1).
(Gamoh et al., 
2001)
Abbreviations: LTP, long-term potentiation; MWM, Morris water maze; NOR, novel object recognition; EPM, elevated plus maze; CFC, contextual fear conditioning; 
SYM, spatial Y-maze; DCX, doublecortin; DG, dentate gyrus; CA1, cornu ammonis 1; CA3, cornu ammonis 3.
Animals Treatment Length of Treatment Measurements Outcomes References
Long Evans 
rats, 2nd 
and 3rd 
generation.
(1) n-3 def diet;
(2) n-3 adeq diet.
8 weeks. Motor activity, 
elevated plus maze, 
Morris water maze.
(2) reversed 
behavioral 
impairment 
compared to (1).
(Moriguchi et al., 
2000)
Donryu 
rats, 2nd 
generation.
(1) Control;
(2) n-3 def diet;
(3) same as (2) + DHA after 
weaning.
7 wks. Brightness- 
discrimination 
learning test.
(3) reversed 
behavioural 
impairment 
compared to (2).
(Ikemoto et al., 
2001)
Table 7. Continued
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on the gut microbiome is still at its infancy, understanding the 
mechanisms behind their potential interplay may open up novel 
attractive strategies to prevent the onset of psychopathologies.
Conclusions
Despite strong evidence pointing out an inverse correlation 
between n-3 PUFAs levels and quality of life/psychiatric diseases, 
the introduction of n-3 PUFAs in clinical practice is still in its 
infancy. The primary reason for this is largely because of incon-
sistent and inconclusive randomized clinical trials. Inadequate 
dosing, inadequate duration, and lack of placebo control are 
major weaknesses in many studies. Use of insensitive and inap-
propriate clinical rating measures is another cause for concern. 
Nonetheless, there are some clear recommendations emerging. 
Low habitual intake of n-3 PUFAs is associated with poorer men-
tal health and, in children, low literacy ability. A  major finding 
is the positive evidence within older healthy adults with age-
related cognitive decline. They benefit most from consuming 
n-3 PUFAs, particularly DHA. However, with the development of 
senile dementia or Alzheimer’s disease, n-3 PUFAs lose efficacy. 
While MDD still remains one of the most discussed and inves-
tigated forms of psychopathology, a clear identification of n-3 
PUFAs as a treatment or adjunct therapy has not yet emerged. 
The evidence base is still weak and RCTs have been inconsist-
ent with many study design limitations. Hence, a major challenge 
ahead is to design and conduct rigorous RCTs to provide proper 
evidence of n-3 PUFA application in clinical conditions, such as 
MDD. Further studies are also required to definitively demon-
strate that n-3 PUFAs reduce the risk of transit from a prepsy-
chotic state to overt schizophrenia. On the other hand, n-3 PUFAs 
are safe and well-tolerated supplements with only mild transient 
side effects. Moreover, being considered as a “natural remedy” and 
due to their relatively low cost, n-3 PUFAs represent an appealing 
option for individuals. While the evidence is not entirely conclu-
sive to make specific recommendations for dietary intake of n-3 
PUFAs, the limited ability of synthesis of n-3 PUFAs de novo and 
their critical role in brain development and functioning make it 
reasonable to include n-3 PUFAs in a balanced daily diet.
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